Intarcia Therapeutics: Diabetes Mellitus, Type 2 trials

The registry lists 11 Diabetes Mellitus, Type 2 studies with Intarcia Therapeutics as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 1Phase 2 1Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 DiabetesCompletedNCT01798264Phase 1Results posted
• Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes MellitusCompletedNCT00943917Phase 2Results posted
• Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on MetforminTerminatedNCT03060980Phase 3
• Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving LiraglutideCompletedNCT02638805Phase 3
• A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1cTerminatedNCT01785771Phase 3
• A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 DiabetesWithdrawnNCT01455922Phase 3
• A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesWithdrawnNCT01455909Phase 3
• A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650CompletedNCT01455896Phase 3
• A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 DiabetesWithdrawnNCT01455883Phase 3
• A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesCompletedNCT01455870Phase 3
• A Study to Evaluate ITCA 650 for the Treatment of Type 2 DiabetesCompletedNCT01455857Phase 3